New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:03 EDTVVTV, AKRX, CALD, EGHT, SSYS, POWR, INVN, HSTM, PRLB, SHORCraig-Hallum to hold a conference
Institutional Investor Conference is being held in Minneapolis on May 28.
News For INVN;CALD;SHOR;POWR;AKRX;PRLB;SSYS;VVTV;HSTM;EGHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2015
09:04 EDTCALDCallidus Software weakness creates buying opportunity, says Roth Capital
Roth Capital predicts that Callidus will report higher than expected Q1 revenue but in-line earnings. The firm expects the company's accelerating revenue to result in upward pressure on the stock. It finds the stock attractive given the company's accelerating growth and reiterates a $22 price target and Buy rating on the shares.
07:52 EDTSSYSStratasys 3D Systems having tough time with competition, says Oppenheimer
After attending a 3d printing conference, Oppenheimer says the outlook for the sector is as strong as ever, but that multiple new players are entering the market. The firm says that the competition is tough for both Stratasys and 3D Systems, although the latter may be seeing more pressure, since most of thee merging technologies seem to target its technologies. The firm keeps an Outperform rating on 3D Systems and a Perform rating on Stratasys.
April 21, 2015
11:57 EDTAKRXAkorn rises, Perrigo slips after Teva makes long-rumored Mylan bid
The shares of drugmaker Akorn (AKRX) are rising after Israeli pharmaceutical company Teva (TEVA) earlier today made a takeover bid for another company in the space, generic drugmaker Mylan (MYL). WHAT'S NEW: Teva announced an $82 per share takeover bid for generic drug maker Mylan earlier today. The latter company said that Teva's takeover offer is a more attractive option for it than acquiring another generic drug maker, Perrigo (PRGO). On April 8, Mylan made a $205 per share takeover offer for Perrigo. Teva's bid comes less than a week after Mylan Chairman Robert Coury said that rumors of potential interest from Teva had been "circulating for some time," but that such a combination was "without sound industrial logic or cultural fit" and would be unlikely to receive antitrust regulatory clearances. ANALYST OPINION: In a note to investors on April 15, RBC Capital analyst Randall Stanicky wrote that Perrigo may have been engaging other companies in talks after Mylan came public with its takeover offer. Stanicky said he saw no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. The analyst added that Acorn is well-positioned as a derivative takeover target following Mylan's offer for Perrigo, noting Acorn's strong growth and high tax rate. In a note to investors yesterday, Citigroup said it believed a potential takeover of Mylan by Teva would have to be friendly after its legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. Citi estimated an $80 per share bid for Mylan would be 25%-35% accretive from 2016 onward for Teva while a $90 per share bid would be 20%-30% accretive. The firm added that it believes it is likely that Mylan received resistance from shareholders since the announcement of its proposed acquisition of Perrigo. PRICE ACTION: In late morning trading, Akorn rose 2.2% to $55.85, Perrigo dropped 2.4% to $193.24, Mylan jumped 9.3% to $74.39, and Teva rose 2.1% to $64.64.
07:09 EDTSSYSMakerBot's Thingverse, 3D Hubs announce new partnership
Subscribe for More Information
06:49 EDTSSYS, PRLBResellers remain unhappy with 3D Systems, says Piper Jaffray
After surveying 62 3D printing resellers and service bureau operators, Piper Jaffray thinks the printing industry experienced a "modest downtick" in Q1 with "much more aggressive sales tactics" and "creative financing" used at the end of the quarter. Regarding Stratasys (SSYS), Piper's feedback did not point to above plan results as was the case in previous quarters. Regarding 3D Systems (DDD), Piper's survey indicated demand was "once again poor" with resellers still unhappy over the company’s channel management and product demand. Piper thinks Stratasys can match consensus estimates for Q1, but no longer views its guidance as conservative. The firm keeps a Neutral rating on both Stratasys and 3D Systems. Its Overweight rated names in the space are Materialise (MTLS) and Proto Labs (PRLB).
April 20, 2015
16:36 EDTHSTMHealthstream sees FY15 operating income down 25%-35%, consensus 32c
Subscribe for More Information
16:33 EDTHSTMHealthstream reports approximately 4.27M total subscribers as of March 31
At March 31, the company had approximately 4.27M total subscribers implemented to use and 4.426M total subscribers contracted to use its subscription-based solutions. “Contracted subscribers” include both those already implemented and those under contract that are in the process of implementation. Revenue recognition commences when a contract is fully implemented.
16:31 EDTHSTMHealthstream reports Q1 EPS 10c, consensus 7c
Reports Q1 revenue $47.2M, consensus $45.62M.
15:37 EDTHSTMNotable companies reporting after market close
Subscribe for More Information
10:00 EDTPRLBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:37 EDTPRLBProto Labs downgraded to Hold from Buy at Needham
April 15, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:13 EDTPOWRPowerSecure has a conference call hosted by JPMorgan
JPMorgan Analyst Coster will host a conference call with Sidney Hinton, President and CEO on April 17 at 10:30 am.
09:02 EDTAKRXRBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
08:19 EDTAKRXAkorn management to meet with Deutsche Bank
Subscribe for More Information
08:15 EDTEGHT8x8, Inc. issued new conferencing and meeting patent
Subscribe for More Information
07:30 EDTSSYSStratasys price target lowered to $82 from $100 at Canaccord
Canaccord lowered its price target on Stratasys to $82 from $100 to reflect a more back-end loaded year driven by lengthening sales cycles at resellers, a challenging integration effort for digital manufacturing, and a less likely imminent recovery for MakerBot. Canaccord maintains its Buy rating on Stratasys.
06:24 EDTAKRXAkorn initiated with an Overweight, $61 target at JPMorgan
Subscribe for More Information
April 14, 2015
10:01 EDTINVNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:22 EDTINVNInvenSense upgraded to Buy from Neutral at Rosenblatt
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use